close 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 74% rachunków inwestorów detalicznych odnotowuje straty w wyniku handlu kontraktami CFD u niniejszego dostawcy. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

Strona główna・Stock List・VIRIDIAN THERAPEUTICS INC
Search

VIRIDIAN THERAPEUTICS INC

Open

SectorHealthcare

27.13 -3.31

Strong Buy

Price update 24 mar 2026, 18:29 UTC

BuySell

Overview

Share price change

24h

Current

Min

26.03

Max

28.15

Key metrics

By Trading Economics

Income

-86M

-120M

Sales

-70M

132K

EPS

-1.08

Profit margin

-91,178.03

Employees

252

EBITDA

-80M

-114M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+50.98% upside

Dividends

By Dow Jones

Next Earnings

5 maj 2026

Market Stats

By TradingEconomics

Market Cap

261M

2.9B

Previous open

30.44

Previous close

27.13

News Sentiment

By Acuity

20%

80%

40 / 350 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

12 / 13.14 Support & Resistance

VIRIDIAN THERAPEUTICS INC Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

DJ

Read

23 mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

DJ

Read

23 mar 2026, 21:51 UTC

Acquisitions, Mergers, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

DJ

Read

23 mar 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

23 mar 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

DJ

Read

23 mar 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

DJ

Read

23 mar 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

DJ

Read

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Global Equities Roundup: Market Talk

DJ

Read

23 mar 2026, 22:42 UTC

Market Talk
Major News Events

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

DJ

Read

23 mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

DJ

Read

23 mar 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

DJ

Read

23 mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

DJ

Read

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

DJ

Read

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

DJ

Read

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

DJ

Read

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

DJ

Read

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

DJ

Read

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

DJ

Read

23 mar 2026, 22:18 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

DJ

Read

23 mar 2026, 22:15 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

DJ

Read

23 mar 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

DJ

Read

23 mar 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

23 mar 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

DJ

Read

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

DJ

Read

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

DJ

Read

23 mar 2026, 21:32 UTC

Earnings

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

DJ

Read

23 mar 2026, 21:10 UTC

Major News Events

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

DJ

Read

23 mar 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

23 mar 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

DJ

Read

23 mar 2026, 20:50 UTC

Market Talk
Earnings
Major News Events

Basic Materials Roundup: Market Talk

DJ

Read

Peer Comparison

Price change

VIRIDIAN THERAPEUTICS INC Forecast

Price Target

By TipRanks

50.98% upside

12 Months Forecast

Average 41.7 USD  50.98%

High 50 USD

Low 29 USD

Based on 12 Wall Street analysts offering 12 month price targets forVIRIDIAN THERAPEUTICS INC - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Based on 12 analysts giving stock ratings to VIRIDIAN THERAPEUTICS INC - Dist in the past 3 months.

Technical Score

By Trading Central

12 / 13.14Support & Resistance

Short Term

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Bearish Evidence

All events are bearish.

Long Term

Strong Bearish Evidence

All events are bearish.

Sentiment

By Acuity

40 / 350 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

901.29

↓-0.96%

JNJ

Johnson and Johnson

235.03

↓-0.28%

ABBV

AbbVie Inc

204.68

↓-0.16%

NVS

Novartis AG

148.56

↑ +0.66%

AZN

AstraZeneca PLC

185.31

↑ +0.58%
help-icon Live chat